Aerie Pharmaceuticals Appoints Peter Lang as Chief Financial Officer | 2022-03-18 | Press Releases


Finance executive with a successful track record in building, deploying and optimizing capital

Brings extensive experience in finance, strategy and business development

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of advanced ophthalmic therapies, today announced that Peter F. Lang will join the company as Chief Financial Officer, effective effective March 18, 2022. He will report to Raj Kannan, Chief Executive Officer of Aerie Pharmaceuticals and become a member of Aerie’s Executive Committee.

“I am delighted to welcome Peter to our leadership team,” said Raj Kannan, Managing Director. managing and deploying capital, including business development and M&A transactions, will be important to maximizing shareholder value.I am confident that Peter will provide strong leadership and be a great addition to the Aerie team.”

Peter Lang added: “I have spent my career working with life sciences companies to help them optimize their growth objectives, funding strategy, capital structure and return on capital, so that they can successfully advance their business plan and meet the needs of patients. I am very excited to join Aerie at this exciting time, with a growing glaucoma business franchise, a strong and innovative pipeline and an experienced team. I look forward to working with Raj and the management team to sustainably grow the business and deliver significant value for patients, clinicians and investors.”

Peter comes to Aerie with over 25 years of experience providing financial, strategic and operational solutions, with deep expertise in healthcare and a particular focus on the biopharmaceutical sector. He has held senior positions in recognized global and specialty investment banks. Additionally, he has extensive experience working with management teams and boards to optimize companies’ growth plans, capital structures and return on capital. During his career, he has helped raise approximately $105 billion in financing and growth capital and advised on more than 40 M&A and business development transactions totaling over $25 billion in value.

Peter joins Aerie from Ridge Advisory, LLC, where he was Managing Director and Partner. Prior to working at Ridge Advisory, Peter held various senior positions in the healthcare investment banking divisions of well-regarded firms including HSBC, Bank of America Merrill Lynch, UBS Investment Bank and Leerink Partners. Peter holds an MBA from the University of Chicago, Booth School of Business, with Top honors. Peter graduated with a double degree, Magna Cum Laude, from the Wharton School of Business and the School of Arts & Sciences at the University of Pennsylvania.

About Aerie Pharmaceuticals, Inc.

Aerie is a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies for the treatment of patients with ocular diseases and conditions, including open-angle glaucoma, dry eye, macular edema diabetic (OMD) and wet age. associated macular degeneration (wet AMD). Rhopressa, Aerie’s first innovative product® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the United States Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with angle-angle glaucoma open or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperaemia, corneal whorls, instillation site pain, and conjunctival hemorrhage. More information about Rhopressa®including the product label, is available at Rocklatan, Aerie’s second innovative product for reducing elevated IOP in patients with open-angle glaucoma or ocular hypertension® (netarsudil (0.02%) and latanoprost ophthalmic solution (0.005%)), was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperaemia, corneal whorls, instillation site pain, and conjunctival hemorrhage. More information about Rocklatan®including the product label, is available at For more information about Aerie Pharmaceuticals, visit

Forward-looking statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We may, in some instances, use terms such as “predicted,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “explore,” “pursue” or other words that convey uncertainty of future events or results to identify these forward-looking statements. Forward-looking statements in this release include statements about our intentions, beliefs, projections , our current outlook, analysis or expectations regarding, among other things, our business franchise and pipeline. By their nature, forward-looking statements involve risks and uncertainties as they relate to events, competitive dynamics, I’ industry developments and other factors beyond our control, and depend on regulatory approvals and economic and environmental circumstances that may or may not occur in the future. or may occur in longer or shorter timeframes than expected. We discuss several of these risks in more detail under “Risk Factors” in our quarterly and annual reports that we file with the Securities and Exchange Commission (SEC). Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements we make in this press release speak only as of the date of this press release. We undertake no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.


Comments are closed.